The Montefiore Einstein Inflammatory Bowel Disease Program is advancing inflammatory bowel disease (IBD) care through a comprehensive, multidisciplinary model that reflects the complex, lifelong nature of Crohn’s disease and ulcerative colitis. The Program integrates specialized clinical care with coordinated support services to address the full spectrum of medical, surgical and psychosocial needs associated with IBD, supporting improved outcomes and quality of life.

Under the leadership of Ruby Greywoode, MD, Director of the Montefiore Einstein Inflammatory Bowel Disease Program, the Program provides specialized care across the full spectrum of disease severity, from newly diagnosed patients to those with advanced, refractory or surgically complex IBD. Our multidisciplinary team of world-renowned gastroenterologists and colorectal surgeons works in close collaboration with subspecialists in rheumatology, dermatology, ophthalmology, nutrition and behavioral health to address the full systemic impact of IBD and deliver seamless, individualized care through a coordinated, team-based approach.

Patients have access to the latest biologic and medical therapies, advanced endoscopic and surgical treatment options and personalized care plans tailored to both clinical needs and lived experience. By integrating nutritional guidance, psychosocial support and long-term disease monitoring into routine care, the Program supports earlier detection of disease activity and more precise treatment planning, while addressing the physical, emotional and social challenges that often accompany chronic gastrointestinal (GI) disease.

Education and research are central to the Program’s mission. The Montefiore Einstein Inflammatory Bowel Disease Program plays a key role in training the next generation of IBD specialists and advancing clinical and translational research focused on improving IBD care delivery and patient outcomes. This work includes examining how behavioral and psychosocial factors, as well as social determinants of health, influence disease course, treatment response and overall well-being. Physician-scientists collaborate across disciplines to translate emerging research into clinical practice, ensuring patients benefit from the most current, evidence-based therapeutic approaches.

“Inflammatory bowel disease is a lifelong condition that often extends beyond the gastrointestinal tract,” said Dr. Greywoode. “Our multidisciplinary approach allows us to address the full scope and complexity of IBD across medical, surgical and psychosocial dimensions so care is better aligned with each patient’s disease course and lived experience.”

Inflammatory bowel disease affects an estimated 2.4 to 3.1 million Americans and encompasses a group of chronic, often debilitating conditions of the GI tract. Characterized by periods of remission and relapse, IBD may lead to serious complications, including the need for bowel resection surgery, and in its most severe forms can be life-threatening. While advances in treatment have significantly improved disease management, a definitive cure has yet to be identified.

Through our integrated care model, the Montefiore Einstein Inflammatory Bowel Disease Program continues to advance how Crohn’s disease and ulcerative colitis are understood and managed, reinforcing Montefiore Einstein’s leadership in advancing comprehensive, patient-centered IBD care and our commitment to improving outcomes and quality of life for individuals living with IBD. Montefiore Einstein is ranked in the top 1% of all hospitals in the nation for gastroenterology and GI surgery, according to U.S. News & World Report, and serves as a national and international referral site for the most complex cases.